Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
160 hedge funds and large institutions have $843M invested in Orexigen Therapeutics, Inc. in 2015 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 57 increasing their positions, 41 reducing their positions, and 21 closing their positions.
62% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 21
39% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 41
29% more capital invested
Capital invested by funds: $654M → $843M (+$189M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
9% more funds holding
Funds holding: 147 → 160 (+13)
35% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $18.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.7M |
| 2 |
Millennium Management
New York
|
+$8.08M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.36M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$6.98M |
| 5 |
TCM
Tamarack Capital Management
Carlsbad,
California
|
+$6.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
-$15.8M |
| 2 |
FAM
Fred Alger Management
New York
|
-$14.7M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$14.3M |
| 4 |
LCP
Lamond Capital Partners
San Francisco,
California
|
-$11.5M |
| 5 |
JP Morgan Chase
New York
|
-$3.52M |
OREX Hedge Fund Activity: Q1 2015 in Review
160 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q1 2015, worth a combined $843M — up 29% from $654M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new OREX positions and 21 closed out — a net gain of 13 holders — while 57 added to existing stakes and 41 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $12.7M. The largest seller was Samlyn Capital, cutting an estimated $15.8M.
- 160 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q1 2015, up from 147 in Q4 2014.
- Funds reported $843M of Orexigen Therapeutics, Inc. stock for Q1 2015, up 29% quarter-over-quarter.
- 34 funds opened new Orexigen Therapeutics, Inc. positions in Q1 2015 and 21 closed out, a net change of +13 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q1 2015 was Point72 Asset Management, an estimated $12.7M added.
- The largest Orexigen Therapeutics, Inc. seller in Q1 2015 was Samlyn Capital, an estimated $15.8M sold.
Based on aggregated 13F filings for Q1 2015.